subject: Chinese enterprises in the European generics market looking for opportunities - Generics - pharmaceutical industries [print this page] Chinese enterprises in the European generics market looking for opportunities - Generics - pharmaceutical industries
When countries become Drugs The largest purchaser, the pharmaceutical companies that market to become the most profitable market. The current European Generic Market, it is. Europe's attitude towards generic drugs than the United States and Japan mild, and the European Association of Generic Drugs (EGA) 2015-year vision plan is also bound to give generic drug companies to bring good opportunities for development. On market prospects, on one hand, increasing aging population in Europe and America, is bound to increase market demand for pharmaceutical products; on the other hand, the prices of generic drugs are working to reduce health care costs for EU member states have considerable temptation, which is a generic coming golden age of the internal driving force.
Then, in the European generics market, where opportunities for Chinese companies?
Since the second half of 2008, global Financial The spread of the crisis our country Export Enterprise faces unprecedented challenges, especially Europe and the United States from overseas orders orders decreased. In China, Pharmaceutical Industry Because of inherent cost advantages, combined with rigid demand for drugs in 2009, export badly affected, especially for export to Europe. China in recent years with the CGMP and COS Certification by the European pharmaceutical companies increased the number of western Europe has been in a class of export growth. According to China Customs statistics, in 2009, China's western class to Europe more than 30% growth in export volume. Among them, Shenghua Yao rapid growth, year on year the number increased 1667 percent over the previous year, the amount grew by 128%; and has a price advantage of the export value of Western medicine in Europe also rose more than 14%.
With EGA generic implementation of the new plan, as well as increase the EU member states to encourage and use of generic drugs, more and more enterprises are starting to join the ranks of generic competition. Piece of cake in the partition process, who share the cost advantage, whoever will have the initiative. As Chinese enterprises have lower production costs, abundant cheap labor and technical capacity advantage, coupled with Environmental protection Low cost, is bound to increase exports of generic drugs in Europe; the same time, large pharmaceutical companies fought with the European generics market, they will certainly increase the quality and cheap API Demand and, as the world's largest exporter of bulk drugs will be the best choice in China.
However, the generics market in Europe continues to face challenges: Although the EGA to develop procedures to speed up generic drugs to be listed, but the original research and patent medicine manufacturers to protect their biggest profits are still diametrically opposed to use of "authorized generics" tactic (Note: original research and patent medicine manufacturers produce their own generic versions of their products, or authorize generic production of a first generic to share its profits, and against other generic drug companies), plus a growing number of pharmaceutical companies to enter the field of generic drugs, how to avoid vicious competition is a problem that must be considered.
